Cero Therapeutics Holdings, Inc. financial data

Symbol
CERO, CEROW on Nasdaq
Location
201 Haskins Way, Suite 230, South San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 22, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 54 %
Debt-to-equity -456 % -577%
Return On Equity 745 % +1802%
Return On Assets -209 % -158%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.21M shares
Common Stock, Shares, Outstanding 5.85K shares
Entity Public Float 5.77M USD +114%
Common Stock, Value, Issued 1 USD -98.9%
Weighted Average Number of Shares Outstanding, Basic 488K shares +5926%
Weighted Average Number of Shares Outstanding, Diluted 488K shares +5926%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 8.36M USD +47.7%
General and Administrative Expense 7.81M USD +40.1%
Operating Income (Loss) -16.2M USD -43.9%
Nonoperating Income (Expense) 2.09M USD -59.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -308K USD -313%
Income Tax Expense (Benefit) 25.8K USD -57.4%
Net Income (Loss) Attributable to Parent -14.1M USD -131%
Earnings Per Share, Basic 233 USD/shares +79.6%
Earnings Per Share, Diluted 233 USD/shares +79.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.2M USD
Assets, Current 4.25M USD +0.02%
Property, Plant and Equipment, Net 383K USD -48.2%
Operating Lease, Right-of-Use Asset 1.07M USD -41.6%
Assets 6.2M USD -15.9%
Accounts Payable, Current 6.21M USD -2.12%
Employee-related Liabilities, Current 5.85K USD -97.6%
Accrued Liabilities, Current 365K USD -68.5%
Liabilities, Current 7.62M USD -13.2%
Operating Lease, Liability, Noncurrent 218K USD -79.7%
Liabilities 7.84M USD -20.5%
Retained Earnings (Accumulated Deficit) -81.4M USD -20.9%
Stockholders' Equity Attributable to Parent -1.63M USD +34.2%
Liabilities and Equity 6.2M USD -15.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -198K USD +35.8%
Net Cash Provided by (Used in) Investing Activities -100K USD
Common Stock, Shares Authorized 45.4M shares
Common Stock, Shares, Issued 5.85K shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -298K USD +3.35%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.33M USD +108%
Deferred Tax Assets, Valuation Allowance 17.6M USD +29.7%
Deferred Tax Assets, Gross 17.6M USD +29.7%
Operating Lease, Liability 1.15M USD -39.2%
Depreciation 76.3K USD -33.3%
Lessee, Operating Lease, Liability, to be Paid 1.23M USD -42.2%
Property, Plant and Equipment, Gross 2.55M USD
Operating Lease, Liability, Current 934K USD +13.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 726K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 726K USD -26.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 73.7K USD -67.7%
Deferred Tax Assets, Operating Loss Carryforwards 12.2M USD +34.9%
Preferred Stock, Shares Issued 4M shares
Deferred Federal Income Tax Expense (Benefit) 182K USD
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 538K USD +17.2%
Additional Paid in Capital 71.3M USD +23.7%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 1.29M USD +511%
Interest Expense 14.4K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%